[Recommendations from the French CML Study Group (Fi-LMC) for BCR-ABL1 kinase domain mutation analysis in chronic myeloid leukemia].
Cayuela, Jean-Michel
[Recommendations from the French CML Study Group (Fi-LMC) for BCR-ABL1 kinase domain mutation analysis in chronic myeloid leukemia]. [electronic resource] - Bulletin du cancer Jan 2020 - 113-128 p. digital
Publication Type: Consensus Development Conference; Journal Article; Practice Guideline; Review
1769-6917
10.1016/j.bulcan.2019.05.011 doi
Antineoplastic Agents--therapeutic use
Catalytic Domain
Clinical Decision-Making
DNA Mutational Analysis--methods
DNA, Neoplasm--analysis
Drug Resistance, Neoplasm--genetics
Drug Substitution
Fusion Proteins, bcr-abl--antagonists & inhibitors
High-Throughput Nucleotide Sequencing
Humans
Leukemia, Myelogenous, Chronic, BCR-ABL Positive--drug therapy
Molecular Biology
Mutation, Missense
Point Mutation
Protein Domains
Protein Kinase Inhibitors--therapeutic use
Role
[Recommendations from the French CML Study Group (Fi-LMC) for BCR-ABL1 kinase domain mutation analysis in chronic myeloid leukemia]. [electronic resource] - Bulletin du cancer Jan 2020 - 113-128 p. digital
Publication Type: Consensus Development Conference; Journal Article; Practice Guideline; Review
1769-6917
10.1016/j.bulcan.2019.05.011 doi
Antineoplastic Agents--therapeutic use
Catalytic Domain
Clinical Decision-Making
DNA Mutational Analysis--methods
DNA, Neoplasm--analysis
Drug Resistance, Neoplasm--genetics
Drug Substitution
Fusion Proteins, bcr-abl--antagonists & inhibitors
High-Throughput Nucleotide Sequencing
Humans
Leukemia, Myelogenous, Chronic, BCR-ABL Positive--drug therapy
Molecular Biology
Mutation, Missense
Point Mutation
Protein Domains
Protein Kinase Inhibitors--therapeutic use
Role